Message #8 From:
NewsBot Date: September 5, 2006 12:32:00 PM
HBSC News Human BioSystems CEO, Harry Masuda to Appear on Market News Radio (www.mn1.com) Wednesday, Sept. 6, 2006
PALO ALTO, Calif.--(BUSINESS WIRE)--Sept. 5, 2006--Human BioSystems (OTCBB:HBSC), announced today that Harry Masuda, CEO, will appear on Market News Radio, Wednesday, September 06, 2006 at 3:00 pm EDT to discuss the company's recent breaking news on the formation of HBS BioEnergy ("HBE") which will operate as a separate company and subsidiary of HBS for the purpose of developing the bio energy business including the two ethanol fuel production facility projects to be acquired from EXL III Group Corporation ("EXL III") pursuant to the Letter of Intent ("LOI") mentioned in the press release dated July 27, 2006.
Mr. Masuda will also be appearing on the following stations this week to update shareholders, listeners, and interested parties, on the formation of HBS BioEnergy.
His scheduled appearances for the week are detailed as follows:
Tuesday, September 5th, 2006
KFWB News 980 Radio - Los Angeles, CA
http://www.kfwb.com
12:00 noon EDT
Wednesday, September 6th, 2006
Market News First - Houston, TX
http://www.mn1.com
3:00 pm EDT
Thursday, September 7th, 2006
TalkStar Radio - Northern & Central Florida
http://www.talkstarradio.com
3:00 pm EDT
Human BioSystems, the developer of preservation platforms for organs and platelets, recently signed a letter of intent to enter into the BioFuels business through the acquisition of two ethanol production facility projects. The Palo Alto based Company, has made significant progress in its nine-year history to maximize their zone of responsibility for the health and welfare of the people and their environments.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
